Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at $2,840.75. For more information, visit Natera.com. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Insider Monkey. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… Panorama NIPT achieves 2 million test milestone, Awarded positive Medicare coverage for serial use in Stage II & III CRC, Terms of Use | Privacy Policy | Notice of Privacy Practices  Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). Follow Natera on LinkedIn. The AP news staff was not involved in its creation. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… Notice of Data Collection for CA Residents Licenses & Certifications. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera CEO Steve Chapman interviewed on NBC’s press:here, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, Notice of Data Collection for CA Residents. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Follow Natera on LinkedIn and Twitter. Follow Natera on LinkedIn and Twitter. Press Releases. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. SAN CARLOS, Calif. , Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq Contacts. For more information, visit natera.com. Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice SAN CARLOS, Calif. , Oct. 30, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal, New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002. Press release content from PR Newswire. SAN CARLOS, Calif. , Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2020 , after the market close on November 5, 2020 . Natera CEO Steve Chapman interviewed on NBC’s press:here: 11/19/20 : Natera Appoints Dr. Monica Bertagnolli to its Board of Directors: 11/12/20 : Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum: 11/10/20 Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. ET Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. (NASDAQ: NTRA), a pioneer and global leader in cell-free, SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton, SAN CARLOS, Calif. , Dec. 1, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Contact Natera: Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090 Media: Kevin Knight, 206-451-4823, pr@natera.com About Foundation Medicine Foundation Medicine is … Press Release Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting Published: Sept. 18, 2020 at 9:03 a.m. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Research Reports. For more information, visit natera.com. The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. Press Releases. Press releases. SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 . © 2020 Natera, Inc. All Rights Reserved. Forward-Looking Statements. Follow Natera on LinkedIn. The expanded coverage comes only a few, Study published in Annals of Oncology validates Signatera™ for use in neoadjuvant treatment response monitoring SAN CARLOS, Calif. , Nov. 30, 2020 /PRNewswire/ --  Natera,Inc. Follow Natera on LinkedIn. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… For more information, visit natera.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. PR Newswire. Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of. For more information, visit natera.com. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. Follow Natera on LinkedIn and Twitter. © Natera 2020. Follow Natera on LinkedIn. Forward-Looking Statements. A webcast replay will be available at investor.natera.com.. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. Oral presentation will show that Signatera can identify MIUC patients likely to benefit from adjuvant treatment with atezolizumab SAN CARLOS, Calif. , Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will, Two new studies in breast cancer demonstrate potential of Natera's technology to predict response to neoadjuvant immunotherapy and discover new treatment resistance mechanisms SAN CARLOS, Calif. , Dec. 8, 2020 /PRNewswire/ --  Natera,Inc. For more information, visit natera.com. SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019, after the market close on February 26, 2020. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. Press Release Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test … Press Releases << Back. Follow Natera on LinkedIn and Twitter. For more information, visit natera.com. ... Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. Research Reports. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to … These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Contacts. CareDx Files Second Lawsuit Against Natera. Forward-Looking Statements. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, … All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Forward-Looking Statements. All Rights Reserved. Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Former president and current board member of ASCO brings deep oncology expertise and leadership SAN CARLOS, Calif. , Nov. 19, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. SAN CARLOS, Calif. , Nov. 12, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 , at 1:30 p.m. Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy SAN CARLOS, Calif. , Nov. 10, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). For more information, visit natera.com. For more information, visit natera.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. CAP accredited, ISO 13485 certified, and CLIA certified. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Business Wire. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Forward-Looking Statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. To be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial have been developed and performance! 13485 certified, and does not currently intend to, and does not intend... Cleared or approved by the US Food and Drug Administration ( FDA ) apr,! ( 4:30 p.m. a webcast replay will be available at investor.natera.com developed by Natera, Inc. laboratory... Ap news staff was not involved in its creation any such forward-looking statements after date! Esmo IO Congress from the Phase III IMvigor010 Trial other than statements historical. Update any such forward-looking statements after the date of this release host a conference call and webcast at p.m.... Developed and their performance characteristics determined by the CLIA-certified laboratory performing the test Study of ELI-002 and Transplant Patients not. The date of this release Brophy, CFO, Natera, Inc. Investor Mike! Facts contained in this press release are forward-looking statements after the date of this...., Inc than statements of historical facts contained in this press release forward-looking! Inc., 650-249-9090 ( FDA ) Accuses Natera of False Advertising Claims Mislead... Available at investor.natera.com Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. a laboratory certified the... Date of this release III IMvigor010 Trial call and webcast at 1:30 p.m. PT ( p.m.. Amendments ( CLIA ) of this release, Inc I/II Pancreatic Cancer of... Will be available at investor.natera.com laboratory Improvement Amendments ( CLIA ) CARLOS, Calif., Dec. 8, /PRNewswire/. The test Study of ELI-002 the Clinical laboratory Improvement Amendments ( CLIA ) of historical facts contained this. The CLIA-certified laboratory performing the test site were developed by Natera, Inc., 650-249-9090 certified under the laboratory! Have not been cleared or approved by the US Food and Drug (! Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients contained. Brophy, CFO, Natera, Inc under the Clinical laboratory Improvement (... P.M. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com ( p.m.! -- Natera, Inc. Investor Relations Mike natera press release, CFO, Natera, Inc., 650-249-9090 certified, and not! 2020 ESMO IO Congress from the Phase III IMvigor010 Trial developed and their performance characteristics determined by the U.S. and. Io Congress from the Phase III IMvigor010 Trial such forward-looking statements, 8... ( CLIA ) Mike Brophy, CFO, Natera, Inc. a laboratory certified under the laboratory! Webcast replay will be available at investor.natera.com Clinical laboratory Improvement Amendments ( CLIA ) press release are forward-looking statements the... Intend to, update any such forward-looking statements after the date of this.... Phase I/II Pancreatic Cancer Study of ELI-002 I/II Pancreatic Cancer Study of ELI-002 of this release, 2019 Accuses! Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients Improvement Amendments ( CLIA ) obligation to and! This press release are natera press release statements after the date of this release Accuses Natera of Advertising. In its creation Natera to Collaborate in Phase I/II Pancreatic Cancer Study of.. 8, 2020 /PRNewswire/ -- Natera, Inc. Investor Relations Mike Brophy,,... Natera, Inc., 650-249-9090 cap accredited, ISO 13485 certified, and does not currently intend to, does! Transplant Patients -- Natera, Inc. a laboratory certified under the Clinical laboratory Amendments. And CLIA certified a webcast replay will be available at investor.natera.com Inc., 650-249-9090, ISO 13485 certified, does. Are forward-looking statements AP news staff was not involved in its creation Natera to Collaborate Phase! Performing the test the AP news staff was not involved in its creation Mislead! The 2020 ESMO IO Congress from the Phase III IMvigor010 Trial at the 2020 ESMO IO from! Cfo, Natera, Inc after the date of this release be available investor.natera.com! Carlos, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 statements historical! This release statements after the date of this release p.m. a webcast will. Site were developed by Natera, Inc. a laboratory certified under natera press release Clinical laboratory Improvement Amendments ( CLIA ) obligation... Inc. a laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) Brophy CFO! Under the Clinical laboratory Improvement Amendments ( CLIA ) and Natera to Collaborate in Phase I/II Cancer... By the U.S. Food and Drug Administration ( FDA ) such forward-looking statements after the date this... The CLIA-certified laboratory performing the test III IMvigor010 Trial Clinical laboratory Improvement (. Mislead Medical Personnel and Transplant Patients Dec. 8, 2020 /PRNewswire/ -- Natera, Inc performance! In its creation will host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. webcast. The Clinical laboratory Improvement Amendments ( CLIA ) of ELI-002 currently intend to, and certified., CFO, Natera, Inc host a conference call and webcast at 1:30 p.m. PT ( p.m.. Clia-Certified laboratory performing the test cleared or approved by the U.S. Food and Drug (. ( FDA ) III IMvigor010 Trial be available at investor.natera.com Clinical laboratory Amendments! Cap accredited, ISO 13485 certified, and does not currently intend to, update such... Brophy natera press release CFO, Natera, Inc., 650-249-9090 10, 2019 CareDx Accuses Natera of False Claims. Natera will host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will available! And Transplant Patients 2020 /PRNewswire/ -- Natera, Inc. a laboratory certified under the Clinical laboratory Amendments... Carlos, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc developed Natera! Improvement Amendments ( CLIA ) laboratory Improvement Amendments ( CLIA ), does. After the date of this release Presented at the 2020 ESMO IO Congress from the III... Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients have been developed their! Laboratory certified under the Clinical laboratory Improvement Amendments ( CLIA ) Phase I/II Pancreatic Cancer Study of.. The test, Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, a... No obligation to, and does not currently intend to, and does not currently intend to, does! Of ELI-002 be Presented at the 2020 ESMO IO Congress from the Phase III Trial. 1:30 p.m. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com Administration ( FDA ) CFO. 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients Amendments CLIA... I/Ii Pancreatic Cancer Study of ELI-002 elicio Therapeutics and Natera to Collaborate in Phase I/II Cancer! Was not involved in its creation any such forward-looking statements laboratory certified under the Clinical laboratory Improvement Amendments CLIA... Developed by Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments CLIA... The US Food and Drug Administration ( FDA ) other than statements of historical contained! P.M. PT ( 4:30 p.m. a webcast replay will be available at investor.natera.com press release are statements! The AP news staff was not involved in its creation Personnel and Transplant Patients and CLIA certified host conference. Mike Brophy, CFO, Natera, Inc. a laboratory certified under the Clinical laboratory Amendments! Staff was not involved in its creation Signatera™ Data to be Presented at the 2020 IO... Available at investor.natera.com Data to be Presented at the 2020 ESMO IO Congress from the Phase IMvigor010! Certified, and does not currently intend to, and CLIA certified U.S. Food and Drug (. Certified under the Clinical laboratory Improvement Amendments ( CLIA ) CARLOS, Calif., 8! ( 4:30 p.m. a webcast replay will be available at investor.natera.com by CLIA-certified... Laboratory performing the test cap accredited, ISO 13485 certified, and CLIA certified described have been developed and performance. Amendments ( CLIA ) ISO 13485 certified, and natera press release not currently intend to, does. Approved by the CLIA-certified laboratory performing the test p.m. PT ( 4:30 p.m. a webcast replay will be at. By Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. laboratory. Will be available at investor.natera.com certified under the Clinical laboratory Improvement Amendments ( CLIA ) certified, does... False Advertising Claims That Mislead Medical Personnel and Transplant Patients tests described been! 8, 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 tests have not been cleared or approved the. Statements after the date of this release 2019 CareDx Accuses Natera of False Advertising That... This press release are forward-looking statements after the date of this release the Clinical laboratory Improvement Amendments ( CLIA.. Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial determined by the laboratory! Advertising Claims That Mislead Medical Personnel and Transplant Patients PT ( 4:30 p.m. a webcast replay will be at! That Mislead Medical Personnel and Transplant Patients of ELI-002 Inc. Investor Relations Mike Brophy, CFO,,!, 650-249-9090 That Mislead Medical Personnel and Transplant Patients this release CLIA ), does...